Long-term effects of normalization of testosterone on variables of the metabolic syndrome in hypogonadal men: the moscow study
L J Gooren1, S Y Kalinchenko2, Y A Tishova2, G J Mskhalaya2, E J Giltay3 & F Saad4,5
Introduction: Men with the metabolic syndrome have low plasma testosterone (T) levels. We aimed to study whether normalization of plasma T in such men improved features of the metabolic syndrome over the longer term.
Design/methods: 145 men, 35 to 70 years, with the metabolic syndrome and hypogonadism (baseline total testosterone level <12.0 nmol/l or calculated free T level <225 pmol/l). They had received treatment for 30 weeks with either parenteral testosterone undecanoate (n=88); TU; 1000 mg i.m.) or placebo (n=57) with measurements at baseline, and after 6 and 18 weeks. After 30 weeks all men received TU for an additional 33 weeks.
Main Outcome Measures: Body mass index (BMI), waist circumference (WC), hip circumference (HC), insulin, glucose, cholesterol, triglycerides, high (HDL) and low density lipoproteins cholesterol (LDL) and triglycerides (TG).
Results: In the men who had received TU for 66 weeks there was a progressive improvement of BMI, WC, HC, insulin, and glucose, with no progressive improvement of cholesterol, LDL, HDL and TG after 30 weeks (Table). In the men who had received placebo for 30 weeks and then shifted to TU for 33 weeks all study variables improved and caught up with the other group over these 33 weeks.
Conclusions: The beneficial effects of normalization of T in hypogonadal men with the metabolic syndrome on BMI, WC, HC, insulin, and glucose are progressive over at least 66 weeks, while maximal effects on cholesterol, LDL, HDL and TG have been reached after 30 weeks